STOCK TITAN
  1. Home
  2. News
  3. CYTO

Altamira Therapeutics Ltd - CYTO STOCK NEWS

Welcome to our dedicated news page for Altamira Therapeutics (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Altamira Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Altamira Therapeutics's position in the market.

News
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Rhea-AI Summary
Altamira Therapeutics announces positive results from the Bentrio trial in seasonal allergic rhinitis, with statistically significant improvements in nasal symptoms, quality of life, and reduced need for relief medication. The publication in a top peer-reviewed journal validates the effectiveness and safety of Bentrio, supporting plans for international expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.86%
Tags
none
-
News
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Rhea-AI Summary
Altamira Therapeutics reports a successful year with a focus on RNA delivery technology, collaborations, and financial improvements. The company achieved an 85% reduction in net loss, eliminated financial debt, and increased shareholders' equity by CHF 14.8 million. Altamira is progressing with preclinical development of RNA delivery platforms for extrahepatic targets, showcasing promising results in cancer and osteoarthritis. Strategic collaborations with Heqet Therapeutics and Univercells Group aim to utilize Altamira's technology for heart tissue regeneration and mRNA vaccine delivery. The company is advancing development programs for KRAS-driven tumors and rheumatoid arthritis, with plans for IND filings in 2025. Altamira divested a stake in its subsidiary, Altamira Medica AG, for cash consideration and financial gain. The subsidiary's key asset, Bentrio nasal spray, demonstrated superior efficacy in allergic rhinitis treatment. Altamira is also focusing on partnering its inner ear therapeutics assets, particularly AM-125 for acute vestibular syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags
earnings
-
News
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
Rhea-AI Summary
Altamira Therapeutics (CYTO) to host Full Year 2023 Financial Results and Business Update Call on April 10, 2024. Founders and executives to provide insights on company performance and future plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.73%
Tags
conferences earnings
News
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
Rhea-AI Summary
Altamira Therapeutics partners with Univercells Group to evaluate the use of its SemaPhore platform for delivering mRNA vaccines, aiming for safer and more accessible vaccination methods. The collaboration aims to test a proprietary mRNA vaccine using Altamira's nanoparticle technology. If successful, a commercial agreement for manufacturing nanoparticle-based mRNA vaccines may follow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.84%
Tags
none
-
News
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) announced the publication of a peer-reviewed study showing enhanced cell transduction with adeno-associated virus (AAV) vectors using their peptide-based delivery technology. The study demonstrated increased potency, potentially reducing AAV immunogenicity and resistance to AAVs in certain cell types. The research evaluated 76 melittin derivatives, including p5RHH, which successfully enhanced cell transduction and transduced cell lines typically resistant to AAVs. In vivo studies in mice showed significant liver transduction enhancements with the addition of p5RHH to AAV capsids of several serotypes, up to four weeks after administration. Altamira's technology has the potential to lower the risk of immune responses and increase the safety of AAV-based vectors, opening new possibilities in gene therapy for cells and tissues typically resistant to transduction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
none
-
News
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) has filed a second provisional patent application with the USPTO for its polyKRASmut siRNA, showing a 65-91% knockdown of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines. The nanoparticles developed as AM-401 aim to provide broad coverage of different KRAS mutations in human cancer treatment. The data suggests that polyKRASmut siRNA has the potential to knock down other untested mutations, making it a promising treatment for severe types of cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
none
News
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
Rhea-AI Summary
Altamira Therapeutics Ltd. (CYTO) to Present at 3rd Annual mRNA-Based Therapeutics Summit. Altamira's flagship programs, AM-401 and AM-411, target KRAS-driven cancer and rheumatoid arthritis, showcasing the technology's ability to enhance therapeutic efficacy. Covadonga Pañeda, Ph.D., Altamira's COO, will present on 'Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles' at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) has announced that it has regained compliance with the minimum bid price requirement set by The Nasdaq Stock Market. This comes after the company was notified of its failure to maintain a minimum closing bid price of at least $1.00 per share for 30 consecutive trading days, leading to a reverse stock split of its common shares at a ratio of 1-for-20. Altamira has now evidenced a closing bid price of its common shares at or greater than $1.00 per share for at least 10 consecutive business days, regaining compliance with Nasdaq Listing Rule 5550(a)(2) and the minimum equity requirements for continued listing on Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
none
-
News
Altamira Therapeutics Provides Investor and Business Update
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) announced a partial spin-off of its Bentrio business, marking the first step in its transition to become a 'pure play' RNA delivery company. The transition is expected to be completed in 2024 through partnering of further legacy assets. The company's spending levels and cash burn are aligned with strategic repositioning and are expected to decrease significantly in 2024. Altamira is now free of financial debt following the early repayment of a convertible loan and expects to regain full compliance with Nasdaq continued listing rules through a reverse split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
823.9%
Tags
none
News
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
Rhea-AI Summary
Altamira Therapeutics Ltd. (Nasdaq: CYTO) will host an Investor and Business Update Call on December 11, 2023, at 8:30 a.m. ET to discuss the development of therapeutics for unmet medical needs. The presentation will be available via teleconference or webcast, and a replay will be accessible through the webcast link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.08%
Tags
conferences
Stock CYTO logo
Altamira Therapeutics Ltd

Nasdaq:CYTO

CYTO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CYTO Stock Data

4.10M
2.22M
0.89%
0.34%
24.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Bermuda
Hamilton

About CYTO

altamira therapeutics (former auris medical) is dedicated to developing therapeutics that address important unmet medical needs. the company is currently active in three areas: • the development of rna therapeutics for extrahepatic therapeutic targets (oligophore™ / semaphore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (bentrio™; commercial) or the treatment of vertigo (am-125; phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (keyzilen® and sonsuvi®, phase 3). the company was founded in 2003, under the name auris medical, and is headquartered in hamilton, bermuda with its main operations in basel, switzerland. the shares of altamira therapeutics ltd. trade on the nasdaq capital market under the symbol “cyto.”